TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15976151

Group type: EXPERIMENTAL
Intervention: CBT+fluoxetine
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 116

Group type: COMPARATOR
Intervention: CBT+placebo
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CBT (any form)
Number of subjects: 116

Group type: COMPARATOR
Intervention: No CBT
Number of subjects: 116
Study: 12215588

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MRI (DWI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: CT
Number of subjects: 54
Study: 10621762

Group type: EXPERIMENTAL
Intervention: Venlafaxine (200-300 mg/day)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Paroxetine (30-40 mg/day)
Number of subjects: 122
Study: 8631039

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1687407

Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Intravenous heparin
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Intravenous beta-blockers
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Steroids before streptokinase infusion
Number of subjects: 831

Group type: COMPARATOR
Intervention: Intravenous heparin and oral anticoagulants
Number of subjects: 831
Study: 6355181

Group type: EXPERIMENTAL
Intervention: Dazoxiben 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dazoxiben (25, 50, 100, 200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30497093

Group type: EXPERIMENTAL
Intervention: Antioxidant administration (α-lipoic acid, vitamin C and E)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (30-s Wingate test)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Antioxidant administration in hypoxia
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sprint exercise
Number of subjects: 9
Study: 28204880

Group type: EXPERIMENTAL
Intervention: γ‐cyclodextrin curcumin formulation (CW8)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: curcumin phytosome formulation (CSL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: standardized unformulated curcumin extract (StdC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: formulation of curcumin with essential oils of turmeric (CEO)
Number of subjects: 12
Study: 27156027

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 75
Study: 23808990

Group type: EXPERIMENTAL
Intervention: IFN α‐2b
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: PEG‐IFN α‐2b
Number of subjects: 1002
Study: 21076897

Group type: EXPERIMENTAL
Intervention: Mini-posterior THA
Number of subjects: 22

Group type: COMPARATOR
Intervention: Two-incision THA
Number of subjects: 22
Study: 19884222

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 17483398

Group type: EXPERIMENTAL
Intervention: Focusing attention on others
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Focusing attention on group identity
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Focusing on individual values
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Focusing attention on others inducing perception of similarity with immigrants
Number of subjects: 3
Study: 14984727

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 600 mg BID (n=23)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (n=24)
Number of subjects: 47
Study: 11590517

Group type: EXPERIMENTAL
Intervention: nelfinavir (750 mg tid), saquinavir soft-gel capsule (SGC) (800 mg tid), and stavudine (40 mg bid)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: ritonavir (400 mg bid), saquinavir-SGC (400 mg bid), and stavudine (40 mg bid)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: delavirdine (400 mg tid), saquinavir-SGC (800 mg tid), and stavudine (40 mg bid)
Number of subjects: 73
Study: 9833606

Group type: EXPERIMENTAL
Intervention: Paracetamol (1 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control subjects (n=10)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Patients with ulcerative colitis
Number of subjects: 10
Study: 8082093

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cisplatin (60 mg/m2) or carboplatin (300 mg/m2), epirubicin (50 mg/m2), etoposide (100 mg/m2) and local irradiation (15 Gy total)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Carboplatin treatment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cisplatin treatment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Non-responders
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 58
Study: 2672755

Group type: EXPERIMENTAL
Intervention: Exercise plus relaxation and breathing therapy (treatment A, n = 76)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Exercise training only (treatment B, n = 80)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Exercise plus relaxation and breathing therapy (treatment A)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Exercise training only (treatment B)
Number of subjects: 156
Study: 31689378

Group type: EXPERIMENTAL
Intervention: Submucosal dexmedetomidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 40
Study: 30945740

Group type: EXPERIMENTAL
Intervention: Upper airway surgical procedure (modified uvulopalatopharyngoplasty and minimally invasive tongue volume reduction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ongoing medical management
Number of subjects: 0
Study: 28795831

Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy for Suicide Prevention (PST-SP)
Number of subjects: 16
Study: 26335316

Group type: EXPERIMENTAL
Intervention: Pedicled supraclavicular artery island flap (PSAIF)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Free radial forearm flap (FRFF)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both interventions (PSAIF and FRFF)
Number of subjects: 27
Study: 23190794

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol + Lisinopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21678494

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study: 18318746

Group type: EXPERIMENTAL
Intervention: Educational and physical programme
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (peripheral registry office and central tax office employees)
Number of subjects: 192
Study: 17344670

Group type: COMPARATOR
Intervention: HD-LV5FU2
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Raltitrexed (R)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: LD-LV5FU2
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Weekly infusional 5FU (WI-FU)
Number of subjects: 294
Study: 12694772

Group type: EXPERIMENTAL
Intervention: Stent-grafting (SG) performed under local anesthesia 9±3 days after CABG (simultaneous)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Stent-grafting (SG) performed during the same anesthesia (synchronous)
Number of subjects: 42
Study: 10955433

Group type: EXPERIMENTAL
Intervention: Digital pelvic floor contraction assessment using the Oxford Scale
Number of subjects: 263

Group type: COMPARATOR
Intervention: Perineometric assessment using PFX perineometer
Number of subjects: 263
Study: 8844389

Group type: EXPERIMENTAL
Intervention: Conventional silicone IOL (Group A)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Higher refractive index silicone IOL (Group B)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: PMMA IOL (Group C)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Phacoemulsification without IOL (Group D)
Number of subjects: 240
Study: 1740938

Group type: EXPERIMENTAL
Intervention: Pre-operative PCS patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-operative PCS patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal males
Number of subjects: 0
Study: 6293716

Group type: EXPERIMENTAL
Intervention: Regimen 1 (10% mannitol, oral neomycin, intravenous cefotaxime)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Regimen 2 (10% mannitol, oral neomycin, intravenous cefotaxime for 24 hours postoperatively)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Regimen 3 (10% mannitol, oral neomycin, cefazolin sodium)
Number of subjects: 99
Study: 30798587

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation with sofosbuvir and ribavirin (Group B)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sofosbuvir plus ribavirin (Group A)
Number of subjects: 41
Study: 28464438

Group type: EXPERIMENTAL
Intervention: Robot-facilitated intervention (TG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Human-facilitated intervention (CG)
Number of subjects: 15
Study: 25932701

Group type: EXPERIMENTAL
Intervention: Passive EHR alert
Number of subjects: 28467

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 28467
Study: 23713245

Group type: EXPERIMENTAL
Intervention: Guizhi Fuling Pill (GFP) and earthworm powder (Group A)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Aspirin (Group B)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Negative control (Group C)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Non-intervention (Group D)
Number of subjects: 408
Study: 21554691

Group type: EXPERIMENTAL
Intervention: Public involvement in quality-indicator choice (direct participation and consultation)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (only clinicians and managers involved in prioritisation)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Public involvement intervention pilot test
Number of subjects: 27
Study: 19540445

Group type: COMPARATOR
Intervention: Conventional technique with burs and solvent (Group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conventional technique with burs and solvent plus clinical operating microscope/ultrasonic tips (Group II)
Number of subjects: 40
Study: 17714175

Group type: EXPERIMENTAL
Intervention: Controlled trials identified in ABS database
Number of subjects: 47
Study: 15185466

Group type: EXPERIMENTAL
Intervention: Guideline-based intervention (comprehensive education, prescribed diet, intensive pharmacological therapy)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Normally-discharged patients (control group)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Guideline-based intervention
Number of subjects: 418
Study: 11773907

Group type: EXPERIMENTAL
Intervention: Low-dose milrinone (25 microg/kg intravenous bolus over 60 minutes followed by a 0.25 microg/kg/min infusion for 35 hours)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: High-dose milrinone (75 microg/kg intravenous bolus over 60 minutes followed by a 0.75 microg/kg/min infusion for 35 hours)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 9650437

Group type: EXPERIMENTAL
Intervention: Standford Hypnotic Susceptibility Scale, Form C (SHSS:C) administered after cold pressor pain protocol
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standford Hypnotic Susceptibility Scale, Form C (SHSS:C) administered before cold pressor pain protocol
Number of subjects: 138
Study: 7648148

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin plus metronidazole
Number of subjects: 169

Group type: COMPARATOR
Intervention: Gentamicin plus metronidazole
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Cover for 3 days
Number of subjects: 169
Study: 2667860

Group type: EXPERIMENTAL
Intervention: Active treatment (carisoprodol, paracetamol, and caffeine)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 913875

Group type: EXPERIMENTAL
Intervention: Safapryn
Number of subjects: 11

Group type: COMPARATOR
Intervention: Butazolidin
Number of subjects: 11
Study: 31087313

Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of colostrum (0.2 mL, 0.1 mL on either side, every 2 hours for 72 hours)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 117
Study: 31010430

Group type: EXPERIMENTAL
Intervention: LAFEW 8 g group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: LAFEW 6 g group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (8 g of milk whey protein)
Number of subjects: 22
Study: 28479240

Group type: EXPERIMENTAL
Intervention: Fesoterodine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26466123

Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23820680

Group type: EXPERIMENTAL
Intervention: Narrow gastric tube reconstruction
Number of subjects: 104

Group type: COMPARATOR
Intervention: Whole stomach reconstruction
Number of subjects: 104
Study: 21442610

Group type: EXPERIMENTAL
Intervention: Multimodal and multidisciplinary perioperative care protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment (historical and concurrent national controls)
Number of subjects: 0
Study: 19558521

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) on mode
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cardiac Resynchronization Therapy (CRT) off mode
Number of subjects: 35
Study: 17729170

Group type: EXPERIMENTAL
Intervention: High utilizers (HU)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Low utilizers (LU)
Number of subjects: 500
Study: 15132312

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 29
Study: 12047395

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study: 9830818

Group type: EXPERIMENTAL
Intervention: Informational letter
Number of subjects: 732

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 732
Study: 8172113

Group type: EXPERIMENTAL
Intervention: Complex dietary patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific combinations of nutrients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single nutrients with antihypertensive properties
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary patterns
Number of subjects: 0
Study: 2697484

Group type: EXPERIMENTAL
Intervention: Phenobarbitone (PB) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulphonylureas (SU) plus metformin (M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 0
Study: 341301

Group type: EXPERIMENTAL
Intervention: Ibuterol 0.75 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Terbutaline 0.50 mg
Number of subjects: 16
Study: 30827757

Group type: EXPERIMENTAL
Intervention: Conventional rTMS
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intermittent theta-burst (iTBS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both rTMS interventions
Number of subjects: 27
Study: 29082824

Group type: EXPERIMENTAL
Intervention: Low frequency (LF) stimulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 26896960

Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance program (12-month, 22-session intervention)
Number of subjects: 223
Study: 25134980

Group type: EXPERIMENTAL
Intervention: ROSE screening program
Number of subjects: 31
Study: 22245896

Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 602

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 602
Study: 19861328

Group type: EXPERIMENTAL
Intervention: Fresh ICSI insemination
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vitrification procedure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vitrification cycles
Number of subjects: 40
Study: 17375982

Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 158
Study: 16045526

Group type: EXPERIMENTAL
Intervention: Outpatient microwave endometrial ablation (MEA) in the postmenstrual phase
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard MEA treatment after drug preparation
Number of subjects: 210
Study: 12230594

Group type: EXPERIMENTAL
Intervention: MIG-99 6.25 mg t.i.d.
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: MIG-99 (2.08 mg; 6.25 mg; 18.75 mg t.i.d.)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: MIG-99
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 147
Study: 10025454

Group type: EXPERIMENTAL
Intervention: Local anesthesia with intravenous conscious sedation and monitored anesthesia care
Number of subjects: 48

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Local anesthesia and General anesthesia
Number of subjects: 48
Study: 7788826

Group type: EXPERIMENTAL
Intervention: 0.05 mg.kg‐1 morphine plus 3 micrograms.kg‐1 clonidine (M+C group; n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.05 mg.kg‐1 morphine alone (M group; n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: M+C group
Number of subjects: 20
Study: 2204698

Group type: EXPERIMENTAL
Intervention: rgp160 vaccine (40 or 80 micrograms)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hepatitis B vaccine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (Hepatitis B vaccine and placebo)
Number of subjects: 15
Study: 913279

Group type: EXPERIMENTAL
Intervention: Aminophenazone in children with acute viral hepatitis
Number of subjects: 23

Group type: COMPARATOR
Intervention: Aminophenazone in healthy children (control group)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Aminophenazone two hours after oral intake in healthy children (control group)
Number of subjects: 23
Study: 31571367

Group type: EXPERIMENTAL
Intervention: Er:YAG laser ablation combined with topical 5% 5-flurouracil application followed by NB‐UVB sessions for 4 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: NB‐UVB sessions for 4 months (control side)
Number of subjects: 40
Study: 31012565

Group type: EXPERIMENTAL
Intervention: Red deer mesenchymal stem cell extract (RCE) cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 40
Study: 28337716

Group type: EXPERIMENTAL
Intervention: high volume on-line hemodiafiltration (hv-OL-HDF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: low-flux bicarbonate dialysis (BHD)
Number of subjects: 36
Study: 25023183

Group type: EXPERIMENTAL
Intervention: Inflated return to player
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Standard 90% return to player
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control (no practice)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Inflated return with pop‐up messages
Number of subjects: 128
Study: 24145742

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (10 g over 3 to 5 days, or 8 g over 2 days)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 564
Study: 22111516

Group type: EXPERIMENTAL
Intervention: Blueberry (BB) ingestion (250 g per day for 6 weeks and 375 g 1 hour prior to exercise)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 25
Study: 19927100

Group type: EXPERIMENTAL
Intervention: ProDisc-L (TDR) at L4/5
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ProDisc-L (TDR) at L5/S1
Number of subjects: 200

Group type: COMPARATOR
Intervention: First cranial adjacent segment to fusion at L5/S1
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: First caudal segment below TDR at L4/5
Number of subjects: 200

Group type: COMPARATOR
Intervention: First caudal segment below fusion at L4/5
Number of subjects: 200
Study: 16987338

Group type: EXPERIMENTAL
Intervention: HES200/0.5
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HES130/0.4
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (group L)
Number of subjects: 60
Study: 12722962

Group type: COMPARATOR
Intervention: Promethazine 25 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fexofenadine 60 mg and 120 mg
Number of subjects: 24
Study: 10657410

Group type: EXPERIMENTAL
Intervention: Hypervolemic (HV) therapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Normovolemic (NV) therapy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both HV and NV therapy
Number of subjects: 82
Study: 9071714

Group type: EXPERIMENTAL
Intervention: Danaparoid sodium (750 anti-Xa units subcutaneously once-daily for 6 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Danaparoid sodium
Number of subjects: 9
Study: 8369391

Group type: EXPERIMENTAL
Intervention: Nonparametric confidence interval procedure for the difference or ratio of two median failure times
Number of subjects: 0
Study: 2428948

Group type: EXPERIMENTAL
Intervention: VAB-6 chemotherapy regimen (cyclophosphamide, vinblastine, bleomycin, dactinomycin, and cisplatin)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: VAB-6 chemotherapy regimen
Number of subjects: 166
Study: 29139056

Group type: EXPERIMENTAL
Intervention: Promoting First Relationships (PFR), a 10-week home visiting parenting intervention
Number of subjects: 0
Study: 28577676

Group type: EXPERIMENTAL
Intervention: Spot urinary creatinine measurement
Number of subjects: 2130
Study: 25714016

Group type: EXPERIMENTAL
Intervention: lncRNA RP11‐160H22.5, XLOC_014172, LOC149086
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lncRNA XLOC_014172, LOC149086
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-operation levels of lncRNAs RP11‐160H22.5, XLOC_014172, LOC149086
Number of subjects: 0
Study: 25885841

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% at 2 mg/kg body weight with 50 μg fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% at 2 mg/kg body weight with 100 μg fentanyl
Number of subjects: 60
Study: 21962070

Group type: EXPERIMENTAL
Intervention: Intravenous iron(III)‐hydroxide sucrose (200 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 24